Mind Medicine (MindMed), Inc. MNMD 深 沪
等待开盘 02-04 09:30:00 美东时间
15.02
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.02
- 总市值 11.43亿
- 52周最高 15.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.70
- 委 比 0.00%
- 总股本 7608.79万
- 历史最高 86.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.20
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Definium Therapeutics (Formerly Mind Medicine) Updates Nasdaq Listing Timeline; Common Shares To Begin Trading Under Ticker DFTX On January 15
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or "Definium") is updating its previous announcement that the Company's Common Shares would begin trading on Nasdaq under the ticker
01-13 20:20
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
Mind Medicine ( ($MNMD) ) just unveiled an announcement. On January 9, 2026, th...
01-12 21:56
Ametek, MindMed, Atai, Prime and KB Home Trending
Analysts are intrested in these 5 stocks: ( ($AME) ), ( ($MNMD) ), ( ($ATAI) ),...
2025-12-27 17:02
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Psyence Biomedical Ltd., a biopharmaceutical company, announced that its nature-derived psilocybin product has been approved for use in its Phase IIb clinical trial for treating Adjustment Disorder in cancer patients. With $9.5 million in cash reserves and no debt, the company is vertically integrated, positioning it as a leader in the psychedelics sector. The trial, conducted at multiple sites, aims to evaluate psilocybin-assisted psychotherapy ...
2025-12-19 12:00
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
2025-12-18 01:42
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
电话会总结 ｜ MindMed(MNMD)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据MindMed业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** - 截至2025年9月30日，现金、现金等价物和投资总额为2.091亿美元 - 第四季度完成股权融资，募集资金总额2.589亿美元，扣除费用后净收益2.428亿美元 **费用支出：** - 研发费用：2025年为3,100万美元，2024年为1,720万美元 - 一般管理费用：2025年为1,470万美元，2024年为760万美元 - 净亏损：2025年为6,730万美元，2024年为1,370万美元 **认股权证收益：** - 2025年认股权证行权带
2025-11-07 12:24
Mind Medicine Q3 EPS $(0.78) Misses $(0.50) Estimate
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.50) by 56 percent. This is a 188.89 percent decrease over losses of $(0.27) per share from the
2025-11-07 05:04
